FDA Approval of Nexviazyme (avalglucosidase alfa) For Treatment of Late-Onset Pompe Disease

Mazen M. Dimachkie, MD, FAAN, FANA, Neuromuscular Division Chief at  The University of Kansas Health System, discusses Pompe disease, a progressive muscle disorder that impairs a person’s ability to move and breathe, and what the FDA approval of Nexviazyme ® (avalglucosidase alfa) means to the Pompe community. 

Dr. Dimachkie is a Professor of Neurology, Executive Vice Chairman and Vice Chairman for Research Programs and Director of the Neuromuscular Division in the Department of Neurology at the University of Kansas Medical Center. As the director of KU Medical Center for Neuromuscular Research, he manages one of the busiest neuromuscular clinical trials units in North America.

He received his medical degree from the American University of Beirut in Lebanon before completing two years of training in Internal Medicine at Saint Agnes Hospital in Baltimore, Maryland. Dr. Dimachkie then completed a residency in Neurology at UT-Houston and fellowship in electromyography and Neuromuscular Disease, both at the University of Texas Health Science Center at Houston (UT-Houston).

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.